Clinical trials: Overweight and Obese Volunteers
Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
Phase 1 Clinical Study of MWN105 Injection in Healthy Chinese Volunteers
This study is a randomized, double-blind, placebo-controlled, single-dose and multiple-dose, dose-escalation phase I clinical trial, aiming to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic…
- Conditions
- Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Trial name
- NCT07801313
- Testing
- MWN105
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Obesity
A Study to Characterize Event Related Potential Markers of Attentional Bias Towards Words and Images of Food
GSK is planning to undertake two anti-obesity drug studies in the area of obesity. In addition to assessment by questionnaires, it would be of significant value to incorporate an objective non-interventional measure of cognitive…
- Trial name
- NCT01366508
- Testing
- High calorie lunch, Breakfast
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.
A study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of AZD9567.
- Trial name
- NCT02760316
- Testing
- AZD9567 10 mg, AZD9567 20 mg, AZD9567 40 mg
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Overweight (BMI > 25)
To Evaluate Efficacy and Safety of Proprietary Healthy Diet Combinations for Weight Management in Overweight Volunteers
This is an open-label, four-arm, randomized, controlled clinical study designed to evaluate the efficacy and safety of a structured Weight Management Program (WMP) in overweight and obese adults with a body mass index (BMI) ≥ 23…
- Trial name
- NCT07452757
- Testing
- Arm II, Arm III, Arm IV
- Where
- India
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Bioagile Therapeutics Pvt. Ltd.
Nausea and Vomiting, Obesity
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one…
- Trial name
- NCT07446439
- Testing
- Tradipitant
- Where
- 10 sites in United States
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals
Healthy
A Study in Healthy Men to Test How BI 456906 is Processed in the Body
This trial is intended to examine the basic pharmacokinetics of BI 456906 and total [14C]-radioactivity, including mass balance, excretion pathways and metabolism following a single subcutaneous (SC) dose of BI 456906 (C-14) in…
- Trial name
- NCT05421338
- Testing
- BI 456906 (C-14)
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Overweight and Obesity
Safety, Tolerability, and Pharmacokinetics of a Single or Multiple Ascending Doses of CPX101
This randomized, double-blind, placebo-controlled Phase I clinical study was designed to evaluate the tolerability and safety, PK profile, immunogenicity of CPX101 in a single dose in healthy participants and multiple doses in…
- Trial name
- NCT06545162
- Where
- 3 sites in China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.
Diabetes Mellitus, Obesity
A Single Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers
The purpose of this study is to evaluate the safety and tolerance of a single intravenous (through a vein) dose of trodusquemine (MSI-1436) in obese, type 2 diabetics.
- Trial name
- NCT00606112
- Testing
- Trodusquemine (MSI-1436)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Genaera Corporation
Insulin Resistance
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BFKB8488A in Otherwise Healthy Overweight and Obese Participants With Likely Insulin Resistance
This study will evaluate the safety and tolerability profile of BFKB8488A following subcutaneous (SC) administration in overweight and obese participants (body mass index [BMI] greater than [>] 27 to less than or equal to [</=]…
- Trial name
- NCT02593331
- Testing
- BFKB8488A
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Obesity
An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.
The goal of this Phase 1 study is to evaluate the safety and tolerability of RT-114 in healthy volunteers. The main objectives are: Primary: To evaluate safety and tolerability of RT-114 when administered as single and multiple…
- Trial name
- NCT06891287
- Testing
- RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity, PG-102
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- RANI Therapeutics
Healthy Volunteers
A Single-dose Study to Investigate the Effect of Injection Site on KAI-9531 Relative Bioavailability in a Range of Body Mass Indices
The main objective of the study is to assess the relative bioavailability of KAI-9531 subcutaneous (SC) injection in the upper arm and thigh compared to the abdomen.
- Trial name
- NCT07044401
- Testing
- KAI-9531
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Kailera
Overweight
A Single Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The purpose of this study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics following a single oral dose.
- Trial name
- NCT00799006
- Testing
- PF-04620110
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers
The purpose of this study is to assess the pharmacokinetics (ie, how the body affects the drug) and pharmacodynamics (ie, how the drug affects the body) of increasing doses of canagliflozin (JNJ-28431754) in healthy obese…
- Trial name
- NCT01756404
- Testing
- Canagliflozin (JNJ-28431754)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity &Amp; Overweight
This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazole
This is a single-center, open-label, single-arm, fixed-sequence Phase I study in healthy participants to evaluate the effect of multiple doses of rifampin or itraconazole on the pharmacokinetics (PK) of VCT220 and its metabolite…
- Trial name
- NCT07056842
- Testing
- Rifampin + VCT220, Itraconazole + VCT220
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Vincentage Pharma Co., Ltd
Metabolic Syndrome, Obesity
Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers
The purpose of this study is to investigate the safety and tolerability of MB12066 after a single oral dose and to investigate the pharmacokinetic characteristics of MB12066 after a single oral dose.
- Trial name
- NCT01285388
- Testing
- MB12066
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Yungjin Pharm. Co., Ltd.
Obesity
Study to Evaluate Methods That Assess the Effect of AZD4017 in Adipose Tissue
The primary purpose of this study is to investigate different methods to evaluate the effect of AZD4017 in adipose tissue after single and multiple doses of AZD4017 in abdominally obese but otherwise healthy subjects.
- Trial name
- NCT01096004
- Testing
- AZD4017
- Where
- Sweden
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers (Diabetes Mellitus, Type 2)
A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.
NNC0519-0130 is a new medicine which may possibly help participants with type 2 diabetes, as it is expected to lower elevated sugar levels in the blood. The medicine may also lower the appetite.
- Trial name
- NCT05363774
- Testing
- NNC0519-0130
- Where
- 3 sites in Denmark, Germany
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight
A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity
This study in healthy men and women compares the injection site experience of the DV3396 pen to that of the PDS290 pens when both pens are used to deliver 0.25 mg semaglutide subcutaneously (sc, under the skin).
- Conditions
- Healthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight, Healthy Volunteers Obesity
- Trial name
- NCT04007107
- Testing
- Semaglutide (administered by DV3396 pen), Semaglutide (administered by PDS290 pen)
- Where
- Netherlands
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers, Overweight
A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide
The study will look at how two different versions of semaglutide reach and stay in the blood after injection. The study aims to show similar levels of semaglutide in the blood when using the different versions.
- Conditions
- Healthy Volunteers, Overweight, Obesity
- Trial name
- NCT04228354
- Testing
- Semaglutide
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers, Overweight or Obesity
A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight
This is an investigator- and participant-blind, randomized, placebo-controlled, parallel-group, Phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of orally administered…
- Trial name
- NCT07499050
- Testing
- RO7795081
- Where
- 2 sites in China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche